Characterization of within-subject responses to fluticasone and montelukast in childhood asthma - Wikidata - wikimedia - TriplyDB

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

http://www.wikidata.org/entity/Q28306277

about

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children Asthma: clinical expression and molecular mechanisms The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial Exhaled nitric oxide measurements: clinical application and interpretation CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients Genetics and pharmacogenetics of the leukotriene pathway Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Imm Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand GPR17 regulates immune pulmonary inflammation induced by house dust mites Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids HLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults.International consensus on (ICON) pediatric asthma Asthma outcomes: exacerbations Asthma outcomes: biomarkers Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.Relationship of Allergy with Asthma: There Are More Than the Allergy "Eggs" in the Asthma "Basket".Role of Leukotrienes and Leukotriene Modifiers in Asthma.The role of pharmacogenomics in improving the management of asthma Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists.Achieving control of asthma in preschoolers.Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications.Evolving Concepts of Asthma.Predictors of remitting, periodic, and persistent childhood asthma.Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study A methodology to establish a database to study gene environment interactions for childhood asthma.The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.The Vitamin D Antenatal Asthma Reduction Trial (VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D supplementation in pregnancy for the primary prevention of asthma and allergies in children.Asthma in sickle cell disease: implications for treatment.Lessons learned from variation in response to therapy in clinical trials.Age-related changes in eosinophil function in human subjects.Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values.Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma.Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation Asthma and other recurrent wheezing disorders in children (chronic)Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.Partner randomized controlled trial: study protocol and coaching intervention.Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial.Repeatability of response to asthma medications.Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma.

P2860

Q24197682-88B9A4AF-8D6A-4DB4-B527-BD8F7FF3E9D1 Q24597331-B46C987A-6380-40EE-B69F-D6448A41CA7C Q24626218-DF41AD36-BCBC-447E-BC09-B2659668CC6C Q24655820-88117260-B70C-45FB-BBB9-3C41D6F7E5DF Q24678480-FF611936-272E-4BEB-B123-1F60DB0168C5 Q28222532-87D3B0A2-A444-4D84-B6D8-2D3ECBD4BD6D Q28254268-2A1F1D7E-6802-42D7-B11E-95223A715E83 Q28275393-27823053-A900-48EC-BDF5-71071132DA62 Q28287399-0CEDB308-3360-4321-9BEF-8AF083FA0A36 Q28512834-8930F4EB-2C03-4D73-B11F-115A5CA12618 Q28943401-064CF1C5-81D6-499E-B0C9-7049CB5FE0D5 Q29417102-559DB7CC-A2A2-4AD2-BC8E-62771A8D9B43 Q30393965-5663D56B-1EC2-428C-8F86-1E2635A6CBAA Q30421935-31BF475A-269B-4909-9DFF-F99B42442F65 Q30425168-713C592D-EBD7-4E79-B9AD-4F2F96295781 Q33227414-9DE7ACF2-C6A3-4040-BF15-370642674462 Q33611380-4345314D-31F3-4C1F-8041-4E9F3C85CDCD Q33664150-3D930725-043E-4B01-B421-C8D990434823 Q33669054-17415E0A-7490-443F-9A56-F71F8E390A35 Q33677296-BE3BC9CA-AFF4-4445-88FF-2176021AE8E3 Q33701635-B4DE23C8-620E-4D90-8617-7AAB30AAEA66 Q33719291-397505AF-5259-4B88-8D0A-1BDE35E44C0E Q33735605-C8A43F7C-4601-43C1-868E-F7FDB6283BA2 Q33750438-87E13047-9892-43EA-98BF-319AE45D3470 Q33755127-5403F6E2-09B3-4475-A38E-8C2C1468D062 Q33763915-A8CACA0E-AA2E-4092-84FA-F02A8609B23B Q33858088-2042A818-12DB-47E3-8EDF-2AAE2922DF2E Q33863995-C25BE807-74E1-4091-B87A-C46013A6B0FA Q33872120-336A63E1-04F1-47F8-9166-17F763C9BDEC Q33999050-95BA92AD-1369-4AF5-94BD-409C96CBECA9 Q34056863-40CBBB97-4610-4736-8621-6680F83948F7 Q34106509-FD743B77-FD94-4095-BD0F-C409A5D736C0 Q34112531-9523729B-C2AD-4C6C-8933-75E6A6093409 Q34124817-56799A54-910F-4DE3-8777-5C86D9259631 Q34150855-E17D948C-61B6-4B08-B124-EE4D0E1E0B77 Q34165210-EE349D4C-EF0D-4E91-9957-E4ECBA875EDB Q34216961-D71100D7-846D-417D-8262-8A93279D1444 Q34303847-C55E8F09-A7E8-4FB0-8858-F344659F937B Q34307611-548E0648-D675-4845-A87C-E0A368AC885B Q34425901-44CE310B-FD04-4AE6-B772-23440C3BC5DF

P2860

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

http://www.wikidata.org/entity/Q28306277

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Characterization of within-sub ...... ontelukast in childhood asthma

@ast

Characterization of within-sub ...... ontelukast in childhood asthma

@en

Characterization of within-sub ...... ontelukast in childhood asthma

@nl

type

label

Characterization of within-sub ...... ontelukast in childhood asthma

@ast

Characterization of within-sub ...... ontelukast in childhood asthma

@en

Characterization of within-sub ...... ontelukast in childhood asthma

@nl

prefLabel

Characterization of within-sub ...... ontelukast in childhood asthma

@ast

Characterization of within-sub ...... ontelukast in childhood asthma

@en

Characterization of within-sub ...... ontelukast in childhood asthma

@nl

P1433

Q28306277-D1E2377D-B764-46FA-9A3E-B564CCC70C27

P1476

Q28306277-B7F83DB0-F265-49B3-B0D6-C86C4F86256A

P2093

Q28306277-47627D33-762A-4B7B-B7FE-B9B39B9BE989

Q28306277-4BB10E90-11C6-493D-B730-9F6FF0FEE318

Q28306277-52C6F4A6-59D9-4ED4-9C0B-39A7D7826939

Q28306277-56EFF5B7-2990-429E-9D51-FB89CD31FFB0

Q28306277-574E0653-39C1-40D4-B1DF-7C769D2A1126

Q28306277-5D822F6D-722E-4924-8BA6-2EFBE65BC25C

Q28306277-8010972B-3993-4257-BE71-642EB53C9531

Q28306277-A0AC53F3-76A2-4493-96DC-0D0FFC9EAFA9

Q28306277-BFE787E1-2F33-4F55-B078-BA8CA5924E99

Q28306277-D91A7F6A-FD60-42C9-826A-1435183731F6

P304

Q28306277-F9F1C41D-BED3-4A2E-BBFB-373A0C48BA11

P31

Q28306277-1B2F6042-2538-4A46-8553-C77967F44E5C

P356

Q28306277-CA1536F9-6983-4A6C-B5CB-AF977AA2F8B5

P407

Q28306277-8D13730F-8F8E-471E-8E55-B2AB099340B5

P433

Q28306277-EF4A0564-584B-46F1-AD75-64EF09A8D136

P478

Q28306277-1D8831E0-1153-447B-A3AA-3101403ABE8D

P50

Q28306277-33AE5529-A970-4C9F-BB96-87BFA13E3C0D

Q28306277-353AFE2D-D2AE-4BA1-B113-A1C9CB91E192

Q28306277-71085501-0FB0-45BB-8A3D-5E875C036E26

Q28306277-905696D8-30D5-4B7F-A15A-7CC7C9A0D977

Q28306277-FAE60579-A9A0-4EB8-A73E-3F956F15DC8E

P577

Q28306277-648D3783-894A-41A9-8968-E3D0036D1CC7

P698

Q28306277-2280EFCC-2BDF-4C21-AC50-39CCD9F02761

P921

Q28306277-C814A4F6-623B-4012-B150-E26B081CFA04

P356

J.JACI.2004.11.014

P1433

The Journal of Allergy and Clinical Immunology

P1476

Characterization of within-sub ...... ontelukast in childhood asthma

@en

P2093

Brenda R Phillips

http://www.w3.org/2001/XMLSchema#string

Christine A Sorkness

http://www.w3.org/2001/XMLSchema#string

Fernando D Martinez

http://www.w3.org/2001/XMLSchema#string

Gary Larsen

http://www.w3.org/2001/XMLSchema#string

Gordon R Bloomberg

http://www.w3.org/2001/XMLSchema#string

Gregory Heldt

http://www.w3.org/2001/XMLSchema#string

Joseph D Spahn

http://www.w3.org/2001/XMLSchema#string

Lynn M Taussig

http://www.w3.org/2001/XMLSchema#string

Mark H Moss

http://www.w3.org/2001/XMLSchema#string

Robert C Strunk

http://www.w3.org/2001/XMLSchema#string

P304

233-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2004.11.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Theresa W. Guilbert

Robert S. Zeiger

Stanley J Szefler

Robert F Lemanske

Leonard B Bacharier

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15696076

http://www.w3.org/2001/XMLSchema#string

P921